These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8820431)

  • 1. Interactions of melphalan with glutathione and the role of glutathione S-transferase.
    Awasthi S; Bajpai KK; Piper JT; Singhal SS; Ballatore A; Seifert WE; Awasthi YC; Ansari GA
    Drug Metab Dispos; 1996 Mar; 24(3):371-4. PubMed ID: 8820431
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism of melphalan by rat liver microsomal glutathione S-transferase.
    Zhang J; Ye Z; Lou Y
    Chem Biol Interact; 2005 Apr; 152(2-3):101-6. PubMed ID: 15840383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans.
    Vahrmeijer AL; Snel CA; Steenvoorden DP; Beijnen JH; Pang KS; Schutrups J; Tirona R; Keizer HJ; van Dierendonck JH; van de Velde CJ; Mulder GJ
    Cancer Res; 1996 Oct; 56(20):4709-14. PubMed ID: 8840988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of the development of melphalan resistance in vitro by selenite.
    Caffrey PB; Zhu M; Frenkel GD
    Biol Trace Elem Res; 1998 Dec; 65(3):187-95. PubMed ID: 9892492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects.
    Kühne A; Sezer O; Heider U; Meineke I; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Brockmöller J; Kaiser R
    Clin Pharmacol Ther; 2008 May; 83(5):749-57. PubMed ID: 17914442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa.
    Srivastava SK; Singhal SS; Hu X; Awasthi YC; Zimniak P; Singh SV
    Arch Biochem Biophys; 1999 Jun; 366(1):89-94. PubMed ID: 10334868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Resistance associated with the glutathione system].
    Gouyette A
    Bull Cancer; 1994 Dec; 81 Suppl 2():69s-73s. PubMed ID: 7727862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q; Bianchi P; Bezwoda WR
    Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid development of glutathione-S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid.
    Caffrey PB; Zhu M; Zhang Y; Chinen N; Frenkel GD
    Cancer Lett; 1999 Feb; 136(1):47-52. PubMed ID: 10211938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan.
    Harkey MA; Czerwinski M; Slattery J; Kiem HP
    Cancer Invest; 2005; 23(1):19-25. PubMed ID: 15779864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance.
    Richardson ME; Siemann DW
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):789-95. PubMed ID: 9369124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of glutathione in cellular resistance to alkylating agents.
    Colvin OM; Friedman HS; Gamcsik MP; Fenselau C; Hilton J
    Adv Enzyme Regul; 1993; 33():19-26. PubMed ID: 8356908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
    Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
    Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
    Chen G; Teicher BA; Frei E
    Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
    Caffrey PB; Frenkel GD
    Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.
    Jones RB
    Cancer Treat Res; 2002; 112():305-22. PubMed ID: 12481722
    [No Abstract]   [Full Text] [Related]  

  • 19. The modulation of alkylating agents.
    Frei E
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):22-4. PubMed ID: 1664143
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients.
    Mulders TM; Keizer HJ; Breimer DD; Mulder GJ
    Drug Metab Rev; 1995; 27(1-2):191-229. PubMed ID: 7641576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.